Media headlines about MacroGenics (NASDAQ:MGNX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MacroGenics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.4648659011379 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $7.46 Million (americanbankingnews.com)
- Eric Blasius Risser Sells 1,000 Shares of MacroGenics Inc (MGNX) Stock (americanbankingnews.com)
- MacroGenics (MGNX) Price Target Increased to $26.00 by Analysts at Morgan Stanley (americanbankingnews.com)
- MacroGenics Inc (MGNX) Expected to Post Earnings of -$1.10 Per Share (americanbankingnews.com)
Shares of MacroGenics (NASDAQ MGNX) traded up $0.13 during trading hours on Tuesday, hitting $29.32. The company had a trading volume of 169,046 shares, compared to its average volume of 268,222. The firm has a market cap of $1,096.12, a P/E ratio of -41.89 and a beta of 2.52. MacroGenics has a 1 year low of $14.36 and a 1 year high of $32.74.
In other news, SVP Eric Blasius Risser sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total transaction of $25,010.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lynn Cilinski sold 23,967 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total value of $599,414.67. The disclosure for this sale can be found here. Insiders have sold a total of 42,967 shares of company stock valued at $1,098,005 over the last three months. Corporate insiders own 8.30% of the company’s stock.
WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/20/macrogenics-mgnx-getting-somewhat-favorable-news-coverage-study-shows/1920111.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.